Published in AIDS Weekly, May 26th, 2003
Tests of the vaccine in mice revealed a transgene product specific CD8+ T-cell response with one dose.
A. R. Pinto and colleagues noted that "human recombinant adenovirus has been studied extensively as vaccine carrier for antigens from different pathogens including those from HIV-1. Although they can induce a very strong cellular and humoral immune response, giving promising results as vaccines, the pre-existing immunity of humans is expected to interfere with the efficacy of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.